SCHEMBL698158

SCHEMBL698158

N#Cc1ccc(N)c(-c2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.49
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 3/20 0.49
GAA P10253 2/20 0.49
HSD17B10 Q99714 3/20 0.48
ADORA2A P29274 3/20 0.45
ADORA1 P30542 2/20 0.45
CYP19A1 P11511 2/20 0.44
METAP2 P50579 1/20 0.44
TSHR P16473 1/20 0.43
HPGD P15428 2/20 0.42
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
ADRA2C P18825 1/20 0.41
MAPK1 P28482 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027443 0.85 ALDH1A1 (0.53) PTGDR2ALDH1A1KDM4EGAAHSD17B10
SCHEMBL21277388 0.83 ALDH1A1 (0.44) ALDH1A1KDM4EGAATSHRKDM1A
SCHEMBL18940861 0.82 ALDH1A1 (0.52) PTGDR2ALDH1A1KDM4EGAAHSD17B10
SCHEMBL3422472 0.82 PTGDR2 (0.53) PTGDR2CYP19A1METAP2TSHRMAOA
SCHEMBL12493346 0.81 PTGS1 (0.49) ALDH1A1KDM4EGAAADORA2AADORA1
SCHEMBL17672828 0.81 PKN1 (0.45) KDM4EADORA2AADORA1CYP19A1TSHR
SCHEMBL9955106 0.81 MMP3 (0.57) ADORA2AADORA1KDM1AMAOAL3MBTL1
SCHEMBL12493176 0.81 ALDH1A1 (0.45) ALDH1A1KDM4EGAAADORA2AADORA1
SCHEMBL17672766 0.80 CYP11B2 (0.58) KDM4EGAAADORA2AADORA1CYP19A1
SCHEMBL17672517 0.80 PTGER1 (0.48) PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648234-B2 Selective androgen receptor degrader (SARD) ligands and methods of use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2023-05-16 US disclosed
US-11648234-B2 Selective androgen receptor degrader (SARD) ligands and methods of use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2023-05-16 US disclosed
US-11648234-B2 Selective androgen receptor degrader (SARD) ligands and methods of use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2023-05-16 US disclosed
US-11591290-B2 Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2023-02-28 US disclosed
US-11591290-B2 Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2023-02-28 US disclosed
US-20220029097-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2022-01-27 US disclosed
US-20220029097-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2022-01-27 US disclosed
EP-3285757-B1 SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF ONCTERNAL THERAPEUTICS INC (US) 2021-09-22 EP disclosed
EP-3285757-B1 SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF ONCTERNAL THERAPEUTICS INC (US) 2021-09-22 EP disclosed
WO-2021136006-A1 NITROGEN-CONTAINING COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC DEVICE 陕西莱特光电材料股份有限公司 2021-07-08 WO disclosed
US-20130153878-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2013-06-20 US disclosed
US-8431250-B2 Aromatic amine derivative, and organic electroluminescent element comprising the same IDEMITSU KOSAN CO., LTD. (JP) 2013-04-30 US disclosed
US-8431250-B2 Aromatic amine derivative, and organic electroluminescent element comprising the same IDEMITSU KOSAN CO., LTD. (JP) 2013-04-30 US disclosed
US-8431250-B2 Aromatic amine derivative, and organic electroluminescent element comprising the same IDEMITSU KOSAN CO., LTD. (JP) 2013-04-30 US disclosed
US-20120112169-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME IDEMITSU KOSAN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120112169-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME IDEMITSU KOSAN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120112169-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME IDEMITSU KOSAN CO., LTD. (JP) 2012-05-10 US disclosed
EP-2423206-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME Idemitsu Kosan Co., Ltd. (JP) 2012-02-29 EP disclosed
CN-102232068-A Aromatic amine derivative and organic electroluminescent element using same IDEMITSU KOSAN CO 2011-11-02 CN disclosed
CN-102056894-A Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORP 2011-05-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220029097-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING THE SAME AR, H1-4, AFF4 PTGDR2 3514/4885ALDH1A1 470/4885KDM4E 586/4885
US-20120112169-A1 AROMATIC AMINE DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME AR, H1-4, AFF4 PTGDR2 3488/4885ALDH1A1 306/4885KDM4E 404/4885
US-11648234-B2 Selective androgen receptor degrader (SARD) ligands and methods of use AR, BRCA1, FSHR PTGDR2 891/4885ALDH1A1 1961/4885KDM4E 1046/4885
US-11591290-B2 Selective androgen receptor degrader (SARD) ligands and methods of use thereof AR, FSHR, UBE2V1 PTGDR2 680/4885ALDH1A1 2132/4885KDM4E 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.